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a b s t r a c t
Agonists for EP4 receptor, a prostaglandin E2 receptor subtype, appear to be a promising therapeutic
strategy for ulcerative colitis (UC) due to their anti-inﬂammatory and epithelial regeneration activities.
However, the clinical development of orally-available EP4 agonists for mild to moderate UC has not yet
been reported. Furthermore, the possibility of an increased risk of colitis-associated cancer (CAC)
through direct proliferative effects on epithelial cells via EP4 signaling has not been ruled out. Recently,
we identiﬁed KAG-308 as an orally-available EP4-selective agonist. Here, we investigated the pharma-
cological and pharmacokinetic proﬁles of KAG-308. Then, we compared KAG-308 and sulfasalazine
(SASP) for their abilities to prevent colitis and promote mucosal healing in a mouse model of dextran
sulfate sodium (DSS)-induced colitis. Finally, the effect of KAG-308 treatment on CAC was evaluated in an
azoxymethane (AOM)/DSS-induced CAC mouse model. KAG-308 selectively activated EP4 and potently
inhibited tumor necrosis factor-α production in peripheral whole blood and T cells. Oral administration
of KAG-308, which showed relatively high bioavailability, suppressed the onset of DSS-induced colitis
and promoted histological mucosal healing, while SASP did not. KAG-308 also prevented colorectal
carcinogenesis by inhibiting colitis development and consequently decreasing mortality in a CAC model,
whereas SASP had marginal effects. In contrast, MF-482, an EP4 antagonist, increased mortality. These
results indicated that orally-administered KAG-308 suppressed colitis development and promoted
mucosal healing. Moreover, it exhibited preventive effects on colorectal carcinogenesis, and thus may
be a new therapeutic strategy for the management of UC that confers a reduced risk of colorectal
carcinogenesis.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Ulcerative colitis (UC) is a chronic inﬂammatory bowel disease
(IBD) with which patients experience intermittent remission and
relapse over many years (Ghosh and Mitchell, 2007). The chronic
inﬂammation increases the risk of colitis-associated cancer (CAC)
and leads to CAC-related death; thus, CAC is regarded as a serious
complication of IBD (Munkholm, 2003; Harpaz and Talbot, 1996).
5-Aminosalicylic acid (5-ASA) is currently used as a ﬁrst-line
therapy for mild-to-moderate UC (Tindall et al., 2007). In the
clinic, treatment with 5-ASA therapy in active UC patients is
useful; however, the ratio of refractory or relapsed cases is also
comparatively high (Nielsen and Munck, 2007; Azad et al., 1977).
Furthermore, the chemoprophylactic effects of 5-ASA on CAC
remains controversial in UC patients (Bernstein et al., 2011; Van
Staa et al., 2005).
The prostaglandin E2 (PGE2) and EP4 receptor, a PGE2 receptor
subtype, plays a critical role in the suppression of inﬂammation
and in the maintenance and repair of intestinal mucosa (Tanaka
et al., 2009; Hatazawa et al., 2006; Kabashima et al., 2002). Several
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studies revealed that EP4 agonists block induction of colitis and
ameliorate established colitis in experimental murine models
(Jiang et al., 2010; Jiang et al., 2007; Nitta et al., 2002). In a clinical
trial, intravenous administration of EP4 agonist was reported to be
effective in treating patients with mild-to-moderate UC who were
refractory to 5-ASA (Nakase et al., 2010). Thus, EP4 agonist
treatment is expected to be an alternative approach to UC.
For the clinical use of EP4 agonist as a new therapeutic strategy
for UC, the development of compounds with orally-available
properties is hugely desirable to improve the convenience of
dosing. However, an orally efﬁcacious EP4 agonist for UC has not
yet been reported, aside from one previous study using micro-
spheres formulation of orally-unstable EP4 agonist (Okamoto et al.,
2012). This may be due to the metabolic instability of several
conventional EP4 agonists. Moreover, there is a possibility of an
EP4 agonist increasing the risk of CAC. EP4 is highly expressed in
colorectal cancer cells, and it is suggested that it plays roles in
their proliferation and motility (Chell et al., 2006). However, there
is no report that reveals the effect of EP4 agonist in CAC
development.
We recently identiﬁed KAG-308, a chemically and metaboli-
cally stable 7,7-diﬂuoroprostacyclin derivative that exhibits EP4
agonist activity (Fig. 1) (Ishibashi et al., 2014). In the current study,
we attempted to clarify the following questions: ﬁrst, whether
orally-administered KAG-308 is well absorbed and prevents coli-
tis; second, whether KAG-308 has mucosal healing (MH) effects
not shared by conventional anti-colitic agents; and third, the effect
of KAG-308 on CAC development risk. We initially investigated the
in vitro pharmacological and pharmacokinetic proﬁles of KAG-308.
Then, we compared the effect of KAG-308 and sulfasalazine
(SASP), a prodrug of 5-ASA, in a dextran sulfate sodium (DSS)-
induced colitis model and in an azoxymethane (AOM)/DSS-
induced CAC model. Finally, to clarify the involvement of the
endogenous PGE2–EP4 axis in CAC development, we evaluated
MF-482, an EP4 antagonist.
2. Materials and methods
2.1. Reagents
KAG-308, (2Z,3aR,4R,5R,6aS)-3,3-diﬂuorohexahydro-4-[(1E,3R,
4R)-3-hydroxyl-4-(3-methylphenyl)-1-penten-1-yl]-2-[4-(1H-tet-
razol-5-yl)butylidene]-2H-cyclopenta[b]furan-5-ol (Fig. 1), was
synthesized by Asahi Glass Co., Ltd. (Tokyo, Japan). MF-482, 4-{1-
[({2,5-dimethyl-4-[4-(triﬂuoromethyl)benzyl]-3-thienyl}carbonyl)
amino]cyclopropyl}benzoic acid, was synthesized by Kaken Phar-
maceutical Co., Ltd. (Tokyo, Japan). DSS (molecular weight 36,000–
50,000) was purchased from MP Biomedicals Inc. (Solon, OH).
AOM and SASP were obtained from Sigma-Aldrich Co. (St.
Louis, MO).
2.2. Receptor binding afﬁnity and functional assays
Competitive binding experiments were performed using
human recombinant EP4-expressing cell membranes (ChemiSC-
REEN EP4 Prostanoid Receptor Membrane Preparation from Milli-
pore, Billerica, MA) and human recombinant prostaglandin I2
receptor (IP)-expressing cell membranes (Kaken Pharmaceutical
Co., Ltd.), according to conventional methods. Brieﬂy, cell mem-
branes and various concentrations of KAG-308 were incubated for
2 h at 25 1C in [3H]–PGE2 (PerkinElmer Inc., Waltham, MA) or [3H]-
Iloprost (PerkinElmer Inc.) -containing binding buffer, and the
bound radioactivity was measured using a microplate scintillation
luminescence counter (TopCount NXT, PerkinElmer Inc.). For
comprehensive functional tests, KAG-308 was examined for
agonistic/antagonistic activities against 158 human G protein-
coupled receptors (GPCRs) including prostanoid receptors using
GPCRProﬁler Services provided by Millipore. To evaluate the
functional agonistic activity of KAG-308 for human and mouse
EP4, activity of luciferase transcribed in response to intracellular
cAMP production was examined using dual luciferase reporter
assays in COS-7 cells transiently expressing human or mouse EP4
receptor. COS-7 cells were incubated with various concentrations
of KAG-308 or PGE2 for 3 h at 37 1C. Reporter assays were
performed using the Dual-Glo Luciferase Assay System (Promega
Corp., Fitchburg, WI) according to the manufacturer's directions.
Inhibition constant (Ki values) from receptor binding assays and
50% effective concentrations (EC50 values) from in vitro functional
assays were calculated.
2.3. Subjects
Ten ml peripheral whole blood samples were collected from
3 healthy volunteers for whole blood cell cultures. In addition, 50 ml
peripheral whole blood samples were collected from 5 healthy
volunteers for isolation of human peripheral blood mononuclear cells
(PBMCs). These samples were withdrawn into blood collection tube
containing sodium heparin. All experiments were approved by the
local ethics committees. Informed consent was obtained from all
healthy volunteers before obtaining samples.
2.4. Animals
Female 6-week-old BALB/c mice were purchased from Japan
SLC (Shizuoka, Japan) or Japan Clea (Tokyo, Japan) and housed
individually in plastic cages with free access to drinking water and
a pelleted basal diet (MF; Oriental Yeast Co., Ltd., Tokyo, Japan),
under controlled conditions of humidity (50720%), light (12/12 h
light–dark cycle) and temperature (2373 1C). All experimental
protocols were approved by the Animal Experimentation Ethics
Committee of Kaken Pharmaceutical Co., Ltd.
2.5. Whole blood cell cultures and isolation of CD4þ T cells
Heparinized peripheral blood samples obtained from 3 healthy
volunteers or 11 mice were diluted 4-fold with IMDM media (Life
Technologies, Carlsbad, CA) supplemented with 1% fetal bovine
serum (FBS), 100 U/ml Penicillin, and 100 mg/ml Streptomycin and
were seeded on 96-well culture plates at 160 μl/well. Human
PBMCs were prepared from heparinized peripheral blood samples
of 5 healthy volunteers according to density-gradient centrifuga-
tion method. The harvested PBMCs were suspended in FACS ﬂow
(BD Biosciences, San Jose, CA) containing 0.5% bovine serum
albumin (BSA). To prepare mouse splenic cells, spleens were
Fig. 1. Chemical structure of 7,7-diﬂuoroprostacyclin derivative KAG-308.
Y. Watanabe et al. / European Journal of Pharmacology 754 (2015) 179–189180
collected from 6 mice and mashed through cell strainer with
40 μm nylon mesh. Obtained splenic cells were suspended in FACS
ﬂow (BD Biosciences) containing 0.5% BSA. CD4þ T cells were
isolated from mouse splenic cells or human PBMCs by magnetic-
activated cell sorting system using autoMACSs Pro Separator
(Miltenyi Biotech, Bergisch Gladbach, Germany) according to the
manufacturer's instructions of CD4þ T cell Isolation Kit II (Miltenyi
Biotech). Isolated CD4þ T cells were cultured in RPMI1640
medium (Life Technologies) supplemented with 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and 10% FBS at 37 1C in 96-well
plates at a density of 7.33105 cells/ml.
2.6. Cytokine production from peripheral whole blood and CD4þ T
cells
Cell cultures of whole blood and CD4þ T cells were pretreated
with various concentrations of KAG-308 for 30 min at 37 1C.
Following this, whole blood cell cultures were stimulated with
lipopolysaccharide (LPS, 100 ng/ml, Sigma-Aldrich Co.), incubated
for 24 h at 37 1C, and then supernatants were harvested. CD4þ T
cells pretreated with KAG-308 were transferred to anti-CD3 pre-
coated T cell activation plates (BD Biosciences), stimulated with
anti-CD28 (Clone E18, 11 mg/ml, BioLegend, San Diego, CA), incu-
bated for 48 h at 37 1C, and then supernatants were harvested. The
concentration of tumor necrosis factor-α (TNF-α) in supernatants
was measured by enzyme linked immunosorbent assay (ELISA)
(Quantikine Mouse TNF-α Immunoassay, R&D Systems) according
to the manufacturer's directions. 50% inhibitory concentrations
(IC50 values) and inhibition rate for TNF-α production in maximum
observed plasma concentration (Cmax) when orally administered
KAG-308 at 0.3 and 1 mg/kg were calculated.
2.7. Pharmacokinetic evaluation
In pharmacokinetic evaluation after single administration of
KAG-308 to mice, KAG-308 was administered to non-fasted mice
intravenously at 0.3 mg/kg and orally at 0.3 and 1 mg/kg. Then,
blood was collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 10 h after
intravenous administration or at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 h
after oral administration (n¼3 at each time point for each
treatment). Plasma samples were obtained from blood by cen-
trifugation (3000 rpm, 15 min, 4 1C) and processed by solid-
phase extraction. The concentration of KAG-308 in plasma was
determined using liquid chromatography–tandem mass spectro-
metry (LC–MS/MS). Areas under the plasma concentration-time
curve covering different intervals (AUC0–10 h, AUC0–24 h, AUC0–1)
and bioavailability were calculated.
2.8. Colitis and CAC induction and drug treatment
Effects of KAG-308 on colitis were investigated using two DSS-
induced colitis models. In the ﬁrst experiment (Experiment 1) to
measure the inhibitory effects of KAG-308, acute colitis was induced in
mice (n¼12 / group) by allowing free access to 2.3% w/v DSS in
drinking water for 8 days. Intact mice (n¼12) were used as a normal
group. KAG-308 was orally administered once daily at doses of 0.3 and
1mg/kg (in distilled water) from 1 day before induction of colitis (day
1) until day 8. Likewise, 10 mg/kg SASP (in distilled water) was
administered over the same time schedule (Fig. 2). In the second
experiment (Experiment 2) to examine the MH effect of KAG-308,
mice (n¼8/group) were treated with 3% w/v DSS in drinking water for
the ﬁrst 9 days, and recovered after replacing DSS-containing drinking
water with distilled water for 12 days. Intact mice (n¼6) were used as
a normal group. KAG-308 was orally administered once daily during
day 9–21 at a dose of 1 mg/kg. SASP was administered at 30 mg/kg
over the same time schedule (Fig. 2). In Experiments 1 and 2, mice
were killed under anesthesia on the last day (day 8 and day 21,
respectively). Excised colon lengths were measured, and the tissues
were longitudinally cut for histological analysis. The effects of KAG-308
in the AOM/DSS-induced CAC (AOM/DSS-CAC) model were also
investigated (Experiment 3). Mice (n¼10/group) were intraperitone-
ally injected with 10 mg/kg AOM on day 0. One week later (day 7),
mice were allowed free access to 2.3 w/v% DSS-containing drinking
water for 7 days followed by free access to distilled water for 14 days.
This DSS/distilled water treatment was repeated three times (distilled
water-drinking was given for only 8 days in the third cycle). Intact
mice (n¼8) were used as a normal group. KAG-308 was orally
administered to mice at 1 mg/kg once daily from one day before the
ﬁrst DSS treatment (day 6) until the day of autopsy (day 64). MF-482
(in 0.5% methylcellulose) and SASP (in distilled water) were adminis-
tered at doses of 0.3 and 10mg/kg, respectively, in the same time
schedule as KAG-308 (Fig. 2). On day 64, mice were killed and blood
samples were collected. Excised colons were measured and processed
as described above.
2.9. Assessment of colitis symptoms
Body weight, stool consistency, and fecal occult blood were
monitored daily. Colitis symptoms were evaluated according to the
stool consistency score, fecal occult blood score and weight loss
score as described in Table 1. Fecal occult blood scores were
estimated using Shionogi II occult blood slides (Shionogi & Co.,
Ltd., Osaka, Japan). Disease activity index (DAI) score was calcu-
lated by sum of stool consistency score, fecal occult blood score
and weight loss score. Area under the time curve (AUC) of DAI
scores was also calculated using the trapezoidal rule.
2.10. Endoscopic procedures
Colitis activity and tumor development were monitored with
AVS thin endoscope system (AVS Co., Ltd., Tokyo, Japan) in both
Experiments 2 and 3. In Experiment 2, endoscopy was performed
on days 9, 15, and 21 after initiation of DSS treatment (Fig. 2). The
severity of mucosal injury was scored at colon region (2 cm)
between 1 and 3 cm from the anus using the modiﬁed method
of the murine endoscopic index of colitis severity (Becker et al.,
2006). In Experiment 3, tumor development was evaluated on
days 35, 56, and 63 after AOM injection (Fig. 2). The number of
colon tumors observed at colon region (2 cm) between 1 and 3 cm
from the anus were counted to determine overall tumor multi-
plicity. In addition, the size and status of every tumor observed
was graded as described previously (Becker et al., 2005). The
endoscopic tumor score was calculated as the sum of tumor grades
observed in each mouse.
2.11. Macroscopic analysis of CAC
To evaluate tumor formation in entire colons of AOM/DSS-CAC
mice, samples were ﬁxed in 5% v/v neutral formalin and macro-
scopically observed to determine the presence of tumors. Tumor
multiplicity was recorded, and individual tumors were measured
to calculate volumes (lengthwidthwidth0.526) as described
previously (Murray et al., 2009). Mean tumor volume was then
determined for individual mice and the overall tumor burden was
calculated by multiplying tumor volume with tumor multiplicity.
2.12. Histological analysis of colitis and CAC
Colonic tissues were ﬁxed in 10% v/v formaldehyde solution,
embedded in parafﬁn and sectioned (2 mm). To visualize goblet cell
depletion and/or crypt loss, sections were stained with Periodic acid-
Schiff (PAS) using a standard staining procedure. PAS-staining
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observations were made in sections at 4 cm distal from the anus using
32 High Power Fields (HPFs) for Experiment 1, and in sections at 1–
3 cm distant from anus using 16 HPFs in Experiment 2, under 200
magniﬁcation (Olympus BX5 microscope; Olympus, Tokyo, Japan).
Changes in the observed PAS staining area, which indicated goblet cell
depletion, were scored as described in Table 1. The severity of goblet
cell damage was calculated as the sum of these scores obtained from
32 HPFs (score range, 0–96) for Experiment 1, and 16 HPFs (score
range, 0–48) for Experiment 2. To evaluate neutrophil inﬁltration,
parafﬁn-embedded sections were stained with hematoxylin and eosin
according to a standard procedure. In the DSS-induced colitis model
(Experiment 2), sections at 1–3 cm from the anus were observed
under 400 magniﬁcation to count neutrophils in the lamina propria.
Total number of neutrophils observed in colon areas was recorded.
Neutrophils were also counted in 32 randomly chosen visual ﬁelds
from colon areas at 0–8 cm from the anus of AOM/DSS-CAC mice
(Experiment 3) under 400 magniﬁcation. Data were presented as
the mean number of inﬁltrated neutrophils per HPF in lamina propria.
For histological tumor analyses, parafﬁn-embedded sections were
stained with hematoxylin and eosin. Colonic adenomas and adeno-
carcinomas were diagnosed as described previously (Ward, 1974). The
number of adenomas and adenocarcinomas on longitudinal colon
sections at 0–8 cm from the anus were counted.
2.13. Immunohistochemistry
Parafﬁn-embedded sections were deparafﬁnized prior to staining.
These sections were stained with anti-mucin 2, anti-CD3, or anti-F4/80
antibody. Detailed information on antibodies and description of the
experimental procedures are provided in the Supplemental materials
and methods. Mucin 2-immunopositive cells were serially observed at
1–3 cm from the anus in Experiment 2. Immunopositive cells were
counted on ﬁve randomly chosen crypts from single HPF under 200
magniﬁcation. Data were indicated as the mean number of immuno-
positive cells per crypt. In the AOM/DSS-CAC model (Experiment 3),
F4/80-immunopositive macrophages and CD3-immunopositive T cells
were counted on 32 randomly chosen visual ﬁelds from colon areas at
0–8 cm from the anus under 400 magniﬁcation. Data were indi-
cated as the mean number of immunopositive cells inﬁltrated into
lamina propria per HPF.
Fig. 2. Schematics of experimental designs 1, 2, and 3.
Table 1
Colitis symptoms score and PAS staining score.
Score Colitis symptoms PAS staining area
Stool consistency Fecal occult blood Weight
loss (g)
0 Normal feces Negative, no change in the slide color (yellow) o1 Broad mucosal staining
1 Spherical feces comprising 50% of
total feces
Slightly positive, faint blue 1–o2 No mucosal staining in the lower 1/3 of colons
2 Banana-shaped feces comprising 50%
of total feces
Weakly positive, weak blue 2–o3 No mucosal staining in the lower 2/3 of colons
3 Banana-shaped feces comprising
Z50% of total feces
Moderately positive, clear blue 3–o4 Dotted weak mucosal staining only in the upper 1/
3 of colons or no mucosal staining
4 Muddy stool Strongly positive, dark blue, color change occurs
instantly with color developer
44 –
5 Watery stool Proctorrhagia – –
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2.14. Measuring cytokine level in blood
Blood was collected, and the serum was isolated by centrifu-
ging at 2200g for 20 min. Levels of TNF-α in serum samples were
measured using ELISA (Quantikine Mouse TNF-α Immunoassay,
R&D Systems) according to the manufacturer's directions.
2.15. Statistical analysis
The mean7S.D. was calculated for all parameters determined.
Statistical analysis was performed using Student's t-test, Dunnett's
test, Mann–Whitney's U-test, and Steel's test and were considered
signiﬁcant when Po0.05. Spearman's rank correlation test was
used to calculate correlation coefﬁcients.
3. Results
3.1. In vitro pharmacological proﬁle of KAG-308
In the receptor binding assay, the Ki values of KAG-308 were 1410,
1540, 32.4, 2.57, and 52.9 nmol/l for human EP1, EP2, EP3, EP4, and IP,
respectively. In comprehensive GPCR assays, KAG-308 exhibited
agonistic activity only for human EP1, EP2, EP3, EP4, and IP toward
158 GPCRs tested, and their EC50 values were 1000, 1000, 160, 17, and
410,000 nmol/l, respectively. KAG-308 had little agonist activity for
the other receptors at a concentration of 1.25 mmol/l, and had no
antagonist activity for the 158 GPCRs. Regarding Gαs signaling through
EP4, KAG-308 also displayed potent agonist activity for human and
mouse EP4 with an EC50 of 0.15 nmol/l and 1.0 nmol/l, respectively in
the dual luciferase reporter assay. Likewise, PGE2 showed an agonist
activity for human and mouse EP4 with an EC50 of 0.19 nmol/l and
0.22 nmol/l, respectively.
3.2. Effect of KAG-308 on TNF-α production from LPS-stimulated
peripheral whole blood and anti-CD3/CD28 stimulated CD4þ T cells
To investigate the effect of KAG-308 on inﬂammatory cytokine
production, an in vitro model producing TNF-α through activation
of peripheral whole blood and CD4þ T cells in human and mouse
was employed. KAG-308 dose-dependently inhibited TNF-α pro-
duction from human and mouse peripheral whole blood stimu-
lated by LPS. It also has similar effects on human and mouse CD4þ
T cells stimulated by anti-CD3/CD28 antibody. The IC50 values of
KAG-308 for TNF-α production in human and mouse peripheral
whole blood were 4.53 nmol/l and 54.2 nmol/l, respectively. In
human and mouse CD4þ T cells, the IC50 values of KAG-308 for
TNF-α production were 0.831 and 92.6 nmol/l, respectively. Inhi-
bitory effects of KAG-308 on TNF-α production from human and
mouse CD4þ T cells were effectively antagonized by MF-482 (data
not shown).
3.3. Pharmacokinetics of KAG-308
Plasma KAG-308 concentrations after intravenous administra-
tion at 0.3 mg/kg declined bi-phasically (Fig. 3A). The plasma
concentration at 0 min (C0min) and AUC0–1, were 285.6 ng/ml
and 55.5 ngh/ml, respectively. Plasma KAG-308 concentrations
after oral administration at 0.3 mg/kg and 1 mg/kg reached time
to peak plasma concentration (Tmax) at 0.5 h and 1.0 h, respec-
tively, and those Cmax were 3.3 ng/ml and 11.5 ng/ml, respectively.
After reached to Tmax, those plasma concentrations gently declined
to 10 h, and that at 1 mg/kg was detected even 24 h after
administration (Fig. 3B). AUC0–10 h at 0.3 mg/kg and 1 mg/kg were
16.6 ngh/ml and 59.0 ngh/ml, respectively, and AUC0–24 h at 1 mg/
kg was 94.0 ngh/ml. Bioavailability when orally administered at
1 mg/kg was 50.8%. Besides, inhibition rates for TNF-α production
from mouse peripheral whole blood in Cmax when administered at
0.3 and 1 mg/kg were estimated at 12.6% and 32.1%, respectively.
In mouse CD4þ T cells, inhibition rates for TNF-α production in
Cmax when administered at 0.3 and 1 mg/kg were estimated at
19.4% and 33.4%, respectively.
3.4. Effect of KAG-308 on colonic mucosal injury development
The preventive effect of KAG-308 on colonic mucosal injury
induced by 2.3 w/v% DSS was investigated in Experiment 1. Colon
shortening observed in the DSS-treated control group was sig-
niﬁcant compared with that observed in the normal group
(Fig. 4A). In histological examinations, crypt loss and goblet cell
depletion were indicated by decreased PAS staining in colon areas
(Fig. 4B). KAG-308 signiﬁcantly suppressed colon shortening at
doses of 0.3 and 1 mg/kg (Fig. 4A). KAG-308 at same doses also
suppressed the increase in PAS staining scores, which indicates
crypt loss associated with goblet cell depletion (Fig. 4B). SASP at
10 mg/kg also signiﬁcantly inhibited colon shortening (Fig. 4A) and
showed a weak but not signiﬁcant inhibitory effect on the increase
in PAS staining scores (Fig. 4B).
3.5. Healing-promoting effect of KAG-308 on colonic mucosal injury
The effects of KAG-308 on MH of inﬂamed mucosa in 3% w/v DSS-
treated mice were examined in Experiment 2. Mice with established
colitis showed a mild weight loss, and displayed severe diarrhea and
occult bleeding. Colon length in the control group was signiﬁcantly
shortened on day 21 compared with that in the normal group. KAG-
308 at 1 mg/kg and SASP at 30 mg/kg restored body weight to normal
levels and recovered colon length, although these effects were not
signiﬁcant. In endoscopic evaluations, mucosal injuries were markedly
increased (Fig. 4C). KAG-308 induced rapid recovery from mucosal
injury in a time-dependent manner, as indicated by signiﬁcant
decreases in endoscopic mucosal injury scores compared with those
in the control group on day 15 and day 21 (Fig. 4C). Likewise, SASP
Fig. 3. Plasma concentrations of KAG-308 after single intravenous or oral administration. (A) KAG-308 at 0.3 mg/kg was intravenously administered and blood was collected
at the indicated time. (B) KAG-308 at 0.3 and 1 mg/kg was orally administered and blood was collected at the indicated time. Data points and bars show the mean7S.D. of
data from 3 animals.
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Fig. 4. Suppression of colitis development and promotion of mucosal healing in the DSS-induced colitis model. (A, B) KAG-308 (KAG) at 0.3 and 1 mg/kg and SASP at 10 mg/
kg were administered once daily from 1 day before induction of colitis, as shown in Fig. 2 (Experiment 1). Mice were killed on day 8, and colon length was measured. Colons
were sectioned for histological staining: (A) Colon length, (B) PAS staining score. Columns and bars show the mean7S.D. from 11 or 12 mice. (C–G) Mice were treated with
KAG-308 (KAG) at 1 mg/kg and SASP at 30 mg/kg as shown in Fig. 2 (Experiment 2). KAG-308 and SASP were administered once daily during day 9–21. (C) Chronological
changes in the endoscopic injury score. Mice were killed on day 21, and colons were sectioned for histological staining and immunohistochemistry. (D) Representative
microscopic images of immunohistochemical staining with anti-mucin 2 antibody on day 21; scale bar, 100 mm; (E) PAS staining score; (F) Number of mucin
2-immunopositive cells; (G) Number of inﬁltrated neutrophils in lamina propria. Columns and bars show the mean7S.D. of data from 6 or 8 animals; **Po0.01 vs. the
normal group; †Po0.05; ††Po0.01 vs. the control group.
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showed similar signiﬁcant decreases in endoscopic scores (Fig. 4C).
With regard to remission of colitis, which was deﬁned by endoscopic
scores of less than 2, endoscopic remission rates were 62.5% and 75.0%
in mice treated with KAG-308 and SASP, respectively, compared with
12.5% for the control group. In histological evaluations, mucosal injury
in the control group was denoted by signiﬁcant increases in PAS
staining scores, and mild decreases in mucin 2-immunopositive goblet
cells, in comparison with those in the normal group (Fig. 4D, E and F).
Marked neutrophil inﬁltration was observed even on day 21 (Fig. 4G).
Treatment with KAG-308 slightly decreased this neutrophil inﬁltra-
tion, signiﬁcantly decreasing PAS staining scores (Fig. 4E), and led to
complete recovery of mucin 2-immunopositive goblet cell numbers
(Fig. 4D and F). In contrast, SASP had no evident effects on these three
histological parameters (Fig. 4D, E, F and G). With regarding to
histological remission of colitis, which was deﬁned by PAS staining
scores of less than 2, histological remission rates in the control, KAG-
308, and SASP groups were 12.5%, 75.0%, and 37.5%, respectively. Thus,
KAG-308 was found to have superior histological MH effects
than SASP.
3.6. Effect of KAG-308 on colitis development in the AOM/DSS-CAC
model
The effects of KAG-308, MF-482, and SASP on chronic colitis
and colorectal carcinogenesis were examined in the AOM/DSS-CAC
model (Experiment 3). One animal of SASP group died during the
ﬁrst cycle and some animals died in all test groups during the third
cycle of DSS/distilled water. The ﬁnal survival rates of the control,
KAG-308, MF-482, and SASP groups were 70%, 90%, 40%, and 60%,
respectively. In the control group, loss in body weight and DAI
scores increased depending on cycles of DSS/distilled water
(Fig. 5A and B), and colon shortening was observed. KAG-308
prominently inhibited body weight loss (Fig. 5A) and signiﬁcantly
inhibited increases in DAI scores during the experimental period
(Figs. 5B and C). In addition, KAG-308 weakly suppressed the colon
shortening, although this effect was not signiﬁcant (Table 2). In
contrast, the body weight in the MF-482 group was markedly
decreased by the third cycle of DSS/distilled water (Fig. 5A). MF-
482 and SASP slightly enhanced increases in DAI score in the ﬁrst
cycle of DSS/distilled water, while the DAI scores remained at the
same level as that in the control group during the second and third
cycles (Fig. 5B). In consequence, AUC of DAI scores obtained in the
MF-482 group was highest of all AUC values for other test groups
(Fig. 5C). On day 64, serum TNF-α level remained slightly high in
the control group (48.774.9 ng/ml) compared to the normal
group (40.772.5 ng/ml) with a signiﬁcant difference, even though
colitis symptoms already improved. In contrast, it was not sig-
niﬁcantly increased in the KAG-308 group (43.672.8 ng/ml).
Histological examinations conducted in the control group showed
that neutrophils, macrophages, and T cells markedly inﬁltrated
into tumor sites and only moderately into non-tumor sites. KAG-
308 signiﬁcantly prevented the inﬁltration of these three types of
cells into both tumor and non-tumor sites (Table 2).
3.7. Effect of KAG-308 on colorectal carcinogenesis development in
the AOM/DSS-CAC model
In the control group, colorectal tumors were endoscopically
observed during the second cycle of DSS/distilled water treatment
and developed in a time-dependent manner (Fig. 6A and B). On
day 64, extensive tumors of various sizes were macroscopically
observed in colorectal areas, and almost all of these were adeno-
carcinomas (Fig. 6C, Table 3). KAG-308 signiﬁcantly inhibited the
formation of colorectal tumors in endoscopic observations (Fig. 6A
and B) and signiﬁcantly inhibited the increase in tumor burden
with decreasing tumor size and multiplicity (Fig. 6C, Table 3).
Histological examinations showed that KAG-308 signiﬁcantly
decreased multiplicity of adenocarcinomas compared with that
observed in the control group (Table 3). In contrast, MF-482 and
SASP slightly promoted tumor formation at day 35 and 56 in
endoscopic examinations, although this was not signiﬁcant
(Fig. 6B and C). There were no signiﬁcant changes in macroscopic
and histological parameters obtained in these groups, possibly
because of small number of surviving mice, except that SASP
increased the multiplicity of adenomas (Table 3).The multiplicity
of adenocarcinomas and the AUC of DAI scores were signiﬁcantly
correlated (r¼0.7918, po0.01).
Fig. 5. Suppression of colitis in the AOM/DSS-CAC model. Mice were treated with
KAG-308 (KAG) at 1 mg/kg, MF-482 (MF) at 0.3 mg/kg, or SASP at 10 mg/kg, as
shown in Fig. 2 (Experiment 3). Test compounds were administered once daily
during cyclic treatment with DSS/distilled water. (A) Chronological changes in body
weight; data points show the mean of data from 5 to 10 animals. (B) Chronological
changes in DAI scores; data points and bars show the mean7S.D. of data from 5 to
10 animals. (C) The AUC of DAI scores from days 10–63; columns and bars show the
mean7S.D. of data from 4 to 9 animals; **Po0.01 vs. the normal group; ††Po0.01
vs. the control group.
Table 2
Effects of tested compounds on colon shortening and inﬁltration of inﬂammatory
cells into colonic mucosa of surviving animals in AOM/DSS-CAC model. The values
represent the mean7S.D. of data from 4 to 9 animals.
Treatment (no. of mice
examined)
Colon length
(mm)
Inﬁltrated cells (cells/HPF)
Neutrophil Macrophage T cell
Normal (8) 103.878.0 0.870.7 8.172.1 9.472.0
Control (7) 91.876.6a 13.873.1a 41.178.3 a 44.379.0a
KAG-308 1 mg/kg (9) 98.677.7 4.472.2b 22.875.9b 23.477.0b
MF-482 0.3 mg/kg (4) 87.873.0 10.875.0 35.4711.0 38.776.1
SASP 10 mg/kg (6) 90.974.5 10.773.8 45.8714.5 36.279.8
a Po0.01 vs. the normal group,
b Po0.01 vs. the control group.
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Fig. 6. Suppression of colorectal tumor formation in the AOM/DSS-CAC model. Mice were administered once daily during cyclic treatment with DSS/DW with KAG-308
(KAG) at 1 mg/kg, MF-482 (MF) at 0.3 mg/kg, or SASP at 10 mg/kg, as shown in Fig. 2 (Experiment 3). (A) Representative endoscopic images of colorectal tumors;
(B) Chronological changes in endoscopic tumor scores and tumor multiplicity. Columns and bars show the mean7S.D. of data from 5 to 10 animals; **Po0.01 vs. the normal
group; †Po0.05; ††Po0.01vs. the control group at corresponding time points. (C) Representative macroscopic images from the anus (left side of the images) to 8 cm of
the colon.
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4. Discussion
In the present study, we conﬁrmed that KAG-308, a newly disco-
vered 7,7-diﬂuoroprostacyclin derivative, is an orally-available EP4-
selective agonist with potent in vitro efﬁcacy. KAG-308 was shown to
be stable to β-oxidation since the carboxy group of α-chain of
prostaglandin skeleton, which is susceptible to β-oxidation, is con-
verted to the tetrazole group; however other EP4 agonists such as
compounds produced by Ono Pharmaceutical Co., Ltd and Allergan,
Inc. have the carboxy group. (Murata et al., 2013; Kambe et al., 2011;
Jiang et al., 2007). Therefore, it had a prolonged plasma half-life and
can maintain an effective plasma concentration for a long time.
Furthermore, it showed high permeability in a study of epithelial cell
monolayers (data not shown). Since the metabolic stability in the body
and the intestinal permeability were improved as seen above, the
bioavailability of KAG-308 could be improved. It was estimated that
the bioavailability of KAG-308 in mice is superior to the only
previously-reported orally-available EP4 agonist (Kambe et al., 2011).
Previous research indicated the effectiveness of EP4 agonist
treatment in animal colitis models. In this study, KAG-308 effec-
tively suppressed the onset of colitis and also inhibited goblet cell
depletion, and its effect was equal to or better than that of SASP.
KAG-308 suppressed colitis when administered orally or subcuta-
neously but not intrarectally at comparable doses in our prelimin-
ary examination. Based on this result, we presumed that orally-
administered KAG-308 showed efﬁcacy against colitis diseases
mainly via systemic circulation. In addition, we ﬁrst demonstrated
that KAG-308 repaired colonic mucosa from established colitis
induced by DSS, while SASP lacked such activity. Speciﬁcally,
therapeutic administration of KAG-308 promoted endoscopic
healing of injured mucosa and increased the number of mucin 2-
positive goblet cells observed by histological methods. Interest-
ingly, SASP also improved endoscopic MH but had no increasing
effect on the number of goblet cells. Apparent differences were
observed between the histological characteristics of mucosa
observed in mice treated with KAG-308 and SASP.
EP4 is strongly expressed in the goblet cells of the rat gastro-
intestinal tract, and its expression is increased in colonic mucosa
during colitis development (Nitta et al., 2002; Northey et al., 2000).
PGE2 is suggested to induce the proliferation of goblet cells (Phillips et
al., 1993). Signaling via EP4 is also shown to stimulate colonic mucin
exocytosis in human colonic epithelial cells and rat colon (Belley and
Chadee, 1999). Thus, our results indicated that KAG-308 may promote
wound healing through the robust secretion of mucus and the
stimulation of goblet cell proliferation. Moreover, it has been reported
that PGE2 regulates murine hematopoietic stem/progenitor cells
through EP4 activation, which cells recruit to injured sites to aid in
tissue repair, implying that KAG-308 elicits epithelial regenerative
repair through mobilization of stem cells (Ikushima et al., 2013;
Kavanagh et al., 2013). However, 5-ASA inhibits production of PGE2
in colonic cells (Serra et al., 2013). Furthermore, it suppresses the
proliferation and induces the apoptosis of colonic epithelial cells
(Reinacher-Schick et al., 2000). These ﬁndings indicate that SASP has
little ability to heal colonic mucosawhen therapeutically administered
in the presence of mucosal injury, although its prophylactic adminis-
tration prevented the onset of mucosal damage mediated via the anti-
inﬂammatory effect. Thus, the difference in efﬁcacy for mucosal injury
between KAG-308 and SASP is thought to be based on the exertion of
opposite actions in the regulation of intestinal epithelial cell function.
The histological MH is essential for true remission in patients with UC
(Neurath and Travis, 2012; Iacucci and Ghosh, 2011). KAG-308
treatment for UC patients is expected to show more prominent
healing effects on injured mucosa than 5-ASA treatment.
It is known that patients with UC who undergo a long-lasting cycle
of ﬂare/remission are at increased risk of CAC; that is, suppression of
colonic inﬂammation and achievement of MH is essential for a
decreased risk of CAC. In a mouse model of AOM/DSS-CAC, it was
reported that colonic inﬂammation characterized by production of
proinﬂammatory cytokines such as TNF-α is related to colorectal
cancer development and its development was suppressed by anti-
TNF-α therapy (Onizawa et al., 2009; Popivanova et al. 2008). In
addition, hepatocyte growth factor, which facilitates the repair of
injured mucosa, inhibits the development of colorectal cancer (Yamaji
et al., 2011). Thus, it is expected that EP4-selective agonists such as
KAG-308 may be able to decrease CAC risk through suppressing
colonic inﬂammation and promoting MH. On the other hand, intest-
inal epithelial proliferation observed in patients with UC in a recovery
phase has the potential to cause an increased incidence of carcinoma
(Seraﬁni et al., 1981). Hence, the promotion of MH during the recovery
phase of UC patients may inﬂuence the induction of colorectal cancer.
The AOM/DSS-CACmodel is characterized by colorectal carcinogenesis
with the recurrence of colitis induction and following recovery from
injured mucosa by repeated DSS treatment; therefore, we considered
that the impact of promotedMH by treatment with EP4 agonist in CAC
development can be evaluated with this model. In this study, we
demonstrated that KAG-308 treatment suppressed repeated inci-
dences of colitis, reduced damage of mucosal injury and strongly
prevented colorectal tumor formation. This result suggests the possi-
bility that the enhanced MH in addition to the anti-inﬂammatory
action by KAG-308 treatment provided beneﬁcial effects for UC
patient without enhancing the incidence of carcinoma.
Endogenous PGE2/EP4 axis is important in diverse physiological
functions. EP4 deﬁciency or EP4 antagonist treatment enhances
cytokine production from inﬂammatory cells and aggravates the
colonic inﬂammation based on impaired mucosal integrity and
intestinal immune response (Kuroda and Yamashita, 2003;
Kabashima et al., 2002), suggesting that endogenous PGE2-EP4
axis is essential for intrinsic anti-colitogenic action. In AOM/DSS-
Table 3
Macroscopic and histological evaluation of colorectal tumor formation isolated from surviving mice in AOM/DSS-CAC model. The values represent the mean7S.D. of data
from 4 to 9 animals.
Treatment (no. of mice
examined)
Macroscopic analyses Histological analyses
Multiplicity (number/
mouse)
Tumor size (mm3/
tumor)
Tumor burden (mm3/
mouse)
Adenoma (number/
section)
Adenocarcinoma (number/
section)
Normal (8) 0.070.0 0.070.0 0.070.0 0.070.0 0.070.0
Control (7) 16.774.8b 5.274.9b 70.6730.4b 0.770.8a 6.472.6a
KAG-308 1 mg/kg (9) 6.874.1 2.171.2 15.7711.2d 1.171.1 1.171.1d
MF-482 0.3 mg/kg (4) 13.8710.6 1.570.3 22.5720.2 1.070.8 2.871.5
SASP 10 mg/kg (6) 24.2712.8 3.270.7 79.5748.2 2.771.6c 4.572.9
a Po0.05.
b Po0.01 vs. the normal group.
c Po0.05.
d Po0.01 vs. the control group.
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CAC model which showed a colorectal carcinogenesis associated
with colitis, COX-2 deﬁciency exhibit increased number of tumors
and higher mortality (Ishikawa and Herschman, 2010). This
indicates that the activation of endogenous COX-2-PGE2 axis acts
cancer-protectively under the colitis condition. Therefore, MF-482
might promote cancer development through the enhancement of
inﬂammatory response and mucosal damage in the presence of
colitis in this study. However, such results seem to conﬂict with
the theory that locally-enhanced production of PGE2 and activated
EP4 signaling in colonic cancer cells promotes tumor growth.
Colorectal cancer development induced by AOM alone which is
not accompanied by inﬂammation was suppressed by COX-2 or
EP4 deﬁciency (Ishikawa and Herschman, 2010; Mutoh et al.,
2002), suggesting that endogenous PGE2–EP4 axis serves as one
of the pro-tumorigenic factors. Reportedly, other EP receptors also
play a role in colorectal carcinogenesis. Different EP receptors
participate in the regulation at different stages (initiation versus
progression) of carcinogenesis (Hull et al., 2004); that is, more
than one EP receptor subtype is involved in carcinogenesis. There-
fore, we consider that the exogenous activation of EP4 alone may
have insigniﬁcant impact on colorectal carcinogenesis. Indeed,
cancer-promoting effects by EP4 agonist treatment has not been
reported in a mouse model of colorectal cancer. In the future, more
research is considered to be needed to clarify the impact of EP4
agonist on colorectal carcinogenesis in in vivo model. Collectively,
our results indicate that blockade of the PGE2–EP4 axis impairs
intestinal homeostasis and leads to exacerbation of CAC but not
suppression, implying that the mucosal PGE2–EP4 axis plays a
critical role in CAC prevention through colitis suppression.
In this study, SASP failed to prevent tumorigenesis in the
AOM/DSS-CAC model. The optimal dosage of SASP is reportedly
variable according to experimental conditions in animal studies
(Reinecke et al., 2012; Petersen et al., 2009, Xu et al., 2009).
Thus, the anti-inﬂammatory actions of SASP at 10 mg/kg may be
insufﬁcient in this model and higher doses, having more potent
anti-inﬂammatory action, would have changed these results.
Clapper et al. (2008) reported that 5-ASA at 75 mg/kg but not
higher doses reduced tumor burden in the AOM/DSS-CAC
model. We also demonstrated that the dose-response curve of
SASP was bell-shaped, and SASP at 10 and 30 mg/kg were
effective, but not at 100 mg/kg in the colitis model in prelimin-
ary experiments. 5-ASA is reported to suppress PGE2 production
from colonic cells and epithelial cell proliferation (Serra et al.,
2013; Reinacher-Schick et al., 2000). Intestinal mucosal protec-
tion/healing and inhibition of cancer cell proliferation in CAC
are considered to be in a reciprocal relationship. That is, SASP at
high doses likely deteriorates the spontaneous intestinal MH,
although it may suppress cancer cell proliferation in CAC.
Therefore, selection of the optimal dose for treating colitis and
CAC is difﬁcult and may result in patients who are refractory to
5-ASA therapy in the clinic.
In conclusion, KAG-308 as an orally-available EP4-selective agonist
should improve the ease of dosing in clinical therapy, a weak point for
the conventional EP4 selective agonist. The oral administration of
KAG-308 is more efﬁcacious than 5-ASA for the prevention and
recovery of DSS-induced colitis and also in prevention of CAC
development in AOM/DSS-CAC model. Therefore, KAG-308 may be
a new therapeutic strategy to treat UC and appears to confer a lower
risk of colorectal carcinogenesis.
Appendix. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.ejphar.2015.02.021.
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